FierceBiotechNew paper could put CRISPR biotechs under pressureFierceBiotech5; Editas was down 0.7% afterhours Friday (and will be presenting at J.P. Morgan later this week), with Intellia down 2.7%, although CRISPR was slightly up by 0.3% afterhours, … Continue reading
Seeking AlphaCrispr Therapeutics: Assessing The Recent Capital FinancingSeeking AlphaOn Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and … Continue reading
Seeking AlphaCrispr Therapeutics: Assessing The Recent Capital FinancingSeeking AlphaOn Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and … Continue reading
Engadget |
Key CRISPR gene editing methods might not work for most humans
Engadget At first glance, CRISPR gene editing looks like the solution to all the world’s ills: it could treat or even cure diseases, improve birth rates and otherwise fix genetic conditions that previously seemed permanent. You might want to keep your … |
Engadget |
Key CRISPR gene editing methods might not work for most humans
Engadget At first glance, CRISPR gene editing looks like the solution to all the world’s ills: it could treat or even cure diseases, improve birth rates and otherwise fix genetic conditions that previously seemed permanent. You might want to keep your … |